DBVT
DBV Technologies S.A.
There isn't enough reported data to score DBVT yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
DBVT Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
DBVT's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
DBVT PE Valuation
DBVT has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
DBVT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect DBVT's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
DBVT Earnings Per Share
DBVT is still losing money, but far less than before: $0.61 per share over the past year, against $13.30 at its worst in mid-2022.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over DBVT in the latest year-over-year earnings comparison.
DBVT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6M | -42% |
| Q2 2026 | $700K | -52% |
| Q1 2026 | $900K | +20% |
| Q4 2025 | $645K | +26% |
| Q3 2025 | $2.8M | +159% |
| Q2 2025 | $1.5M | +26% |
| Q1 2025 | $753K | -46% |
| Q4 2024 | $511K | -94% |
DBVT's revenue has slid since its 2023 peak: $2M last quarter, down 42% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -4050% | -2814 points |
| Q2 2026 | -7229% | -4422 points |
| Q1 2026 | -5322% | -1787 points |
| Q4 2025 | -6985% | -2315 points |
| Q3 2025 | -1236% | +1593 points |
| Q2 2025 | -2806% | +109 points |
| Q1 2025 | -3535% | -1505 points |
| Q4 2024 | -4669% | -4535 points |
DBVT's operating margin was −4050% last quarter, down 2814 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over DBVT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over DBVT on profitability, with a higher operating margin.
DBVT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$53.7M | -$21.1M |
| Q2 2026 | -$53M | -$19.1M |
| Q1 2026 | -$49.5M | -$29.8M |
| Q4 2025 | -$35.5M | -$23.4M |
| Q3 2025 | -$32.6M | -$9.7M |
| Q2 2025 | -$33.9M | +$1.9M |
| Q1 2025 | -$19.7M | +$16.3M |
| Q4 2024 | -$12.1M | +$1.9M |
DBVT has burned cash in almost every quarter: −$192M over the past year, against −$98M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over DBVT on cash generation, producing positive trailing cash flow while its opponent burns cash.
DBVT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4% | +17.5M shares |
| 1 year | +235% | +317M shares |
| 3 years | +4700% | +442M shares |
DBVT has 451M diluted shares, up 235% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over DBVT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
DBVT Net Leverage
DBVT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
DBVT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.9 | Neutral |
| Stochastic | 28.1 | Neutral |
DBVT's weekly RSI is 42 (neutral) and its Stochastic is 28 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
DBVT PE vs Healthcare Sector
DBVT has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
DBVT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.3 | 11% above |
| 20 week MA | $12.5 | 8.3% below |
| 50 week MA | $16.8 | 32% below |
| 100 week MA | $12.7 | 10% below |
| 200 week MA | $13.0 | 12% below |
DBVT has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 12% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over DBVT on trend strength, trading above more of its moving averages.
DBVT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $37.4 | $25.8 | -31% |
| 2021 | $25.8 | $16.9 | -34% |
| 2022 | $16.9 | $14.4 | -15% |
| 2023 | $14.4 | $9.55 | -34% |
| 2024 | $9.55 | $3.19 | -67% |
| 2025 | $3.19 | $19.2 | +501% |
| 2026 YTD | $19.2 | $11.4 | -40% |
DBVT's yearly returns have swung widely, from +501% in 2025 to −67% in 2024. It's down 40% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over DBVT on returns for 2026, with the stronger performance.